BioSpace News Archive

Nautilus Biotechnology, Inc. announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced it had received written agreement regarding the overall design from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the Company’s ongoing pivotal Phase 3 clinical trial for AXPAXLI (axitinib intravitreal implant), for the treatment of wet age-related macular degeneration (wet AMD), which the Company refers to as the SOL trial.

The Leukemia & Lymphoma Society, the largest private funder of blood cancer research, announced $65 million in new grants to 78 research teams across seven countries.

I-Mab today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company’s 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting, taking place November 1-5, 2023

Gate Bioscience, a biotechnology company creating a new class of medicines called Molecular Gates, unveiled the company and its scientific platform.

Boston Scientific Corporation (NYSE: BSX) will participate in Stifel’s 2023 Healthcare Conference on Tuesday, November 14, 2023.

INOVIO today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan.

Aptatek BioSciences, Inc. has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director.

BioSig Technologies, Inc. announced that the U.S. Patent and Trademark Office has awarded several new utility patents covering the Company’s PURE EP™ digital signal processing technology.

Eterna Therapeutics Inc. today announced the appointment of James Bristol, Ph.D., to its Board of Directors.